LLAI.L

LungLife AI, Inc
LungLife AI, INC - Directorate Change
25th October 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5520J
LungLife AI, INC
25 October 2024
 

LungLife AI, Inc.
(the "Company" or "LungLife")

 

Directorate Change

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the resignation of James McCullough, as a non-executive director of the company, with effect from 24 October 2024.

 

James McCullough has taken the decision to step down from the Board to focus on his Executive role at Renalytix plc.

 

Following this resignation, the Board remains confident in its current composition, which continues to reflect a strong balance of skills, experience, and independence. At this time, the Board has no immediate plans to seek a replacement, as it believes the current structure, together with the Scientific Advisory Board, is well-positioned to support the company's ongoing growth and development and does not impact the composition and independence of our committees.

 

Roy Davis, Non-Executive Chairman commented "On behalf of the Board I would like to thank James for his significant contribution as Non-executive Director to LungLife AI and wish him all the best in the future. Whilst we will miss his insights, the Board remains strong and independent, supported by our Scientific Advisory Board, and we are confident in our ability to continue delivering on our long-term goals for the business."  

 

 

For further information please contact:

 

LungLife AI, Inc.

www.lunglifeai.com

Paul Pagano, CEO 

via investors@lunglifeai.com

David Anderson, CFO

 

 

 

Investec Bank plc (Nominated Adviser & Broker)

Tel: +44 (0)20 7597 5970

Virginia Bull / Lydia Zychowska / Sara Wallace




Goodbody (Joint Broker)

Tel: +44 (0) 20 3841 6202

Tom Nicholson / Cameron Duncan

 

 

 

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

 

Our Purpose is to be a driving force in the early detection to lung cancer.  And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFLFITISLSFIS]]>
TwitterFacebookLinkedIn